Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, et al. Outcomes after second hematopoietic cell transplantation in children and young adults with relapsed acute leukemia. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25:301–6.
Kuhlen M, Willasch AM, Dalle J, Wachowiak J, Yaniv I, Ifversen M, et al. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL- SCT 2003/2007 trial. Br J Haematol. 2018;180:82–9.
Google Scholar
Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors—the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33:1265–74.
Google Scholar
González Vicent M, Molina B, Panesso M, Bueno D, Pascual A, Vinagre S, et al. Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Español de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee. Cytotherapy. 2025;27:438–45.
Google Scholar
Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295–307.
Google Scholar
Kato M, Horikoshi Y, Okamoto Y, Takahashi Y, Hasegawa D, Koh K, et al. Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplant. 2012;47:1307–11.
Google Scholar
Naik S, Martinez C, Leung K, Sasa G, Nguyen NY, Wu MF, et al. Outcomes after second hematopoietic stem cell transplantations in pediatric patients with relapsed hematological malignancies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21:1266–72.
Yaniv I, Krauss AC, Beohou E, Dalissier A, Corbacioglu S, Zecca M, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study. Biol Blood Marrow Transplant. 2018;24:1629–42.
Google Scholar
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.
Google Scholar
Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4:5414–24.
Google Scholar
Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40:945–55.
Google Scholar
Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, et al. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022;6:4251–5.
Google Scholar
Oporto Espuelas M, Burridge S, Kirkwood AA, Bonney D, Watts K, Shenton G, et al. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme. Blood Cancer J. 2024;14:1–10.
Google Scholar
Grupp SA, Maude SL, Rives S, Baruchel A, Boyer M, Bittencourt H, et al. Tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia: updated analysis of the ELIANA clinical trial. Biol Blood Marrow Transplant. 2019;25:S126–7.
Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39:1650–9.
Google Scholar
Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives S, Myers GD, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J Immunother Cancer. 2021;9:e002287.
Google Scholar
Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41:1664–9.
Google Scholar
John S, Curran KJ, Hall EM, Keating AK, Baumeister SHC, Nikiforow S, et al. Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025;9:5249–62.
Google Scholar
Ortiz-Maldonado V, Galimard JE, Ottaviano G, Alonso-Saladrigues A, Farhan SY, Vuyyala S, et al. Real-world outcomes of CD19-targeted CAR T-cell therapy in adult and pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL): insights from the GoCART coalition on behalf of the PDWP, ALWP, and CTIWP of the EBMT. Blood. 2024;144:2333.
Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Bücklein VL, et al. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Adv. 2023;7:2436–48.
Google Scholar
Dourthe ME, Baruchel A. CAR T-cells for acute leukemias in children: current status, challenges, and future directions. Cancer Metastasis Rev. 2025;44:47.
Google Scholar
Barsan V, Li Y, Prabhu S, Baggott C, Nguyen K, Pacenta H, et al. Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. eClinicalMedicine. 2023;65:102268.
Google Scholar
Dourthe ME, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, Méchinaud F, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35:3383–93.
Google Scholar
Myers RM, Taraseviciute A, Steinberg SM, Lamble AJ, Sheppard J, Yates B, et al. Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:932–44.
Google Scholar
Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022;139:3376–86.
Google Scholar
Chen YH, Zhang X, Cheng YF, Chen H, Mo XD, Yan CH, et al. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2020;22:755–61.
Google Scholar
Feng J, Huang H, HU Y. A multicenter study of CAR-T cell therapy for relapse of B-ALL post allogeneic stem cell transplantation. Blood. 2023;142:3485.
Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, et al. Outcomes after nonresponse and relapse post-tisagenlecleucel in children, adolescents, and young adults with B-cell acute lymphoblastic leukemia. J Clin Oncol. 2023;41:354–63.
Google Scholar
Locatelli F, del Bufalo F, Quintarelli C. Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Haematologica. 2024;109:1689–99.
Google Scholar
Fu S, Yu Y, Zhang M, Feng J, Wang W, Tu S, et al. Long-term follow-up of CD19 chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2026;28:102074.
Google Scholar
Hu Y, Wang J, Wei G, Yu J, Luo Y, Shi J, et al. A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. Bone Marrow Transplant. 2019;54:1208–17.
Google Scholar
Brudno JN, Somerville RPT, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112–21.
Google Scholar
Luo Y, Gao L, Liu J, Yang L, Wang L, Lai X, et al. Donor-derived anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial. eClinicalMedicine. 2024;67:102377.
Google Scholar
Liu L, Hu Y, Huang R, Li Y, Tu S, Chen S, et al. Recipient-derived vs. donor-derived CAR-T-cell therapy in relapsed B-cell acute lymphoblastic leukemia patients after transplantation: a multi-center retropective study. Chin Med J. 2026;139:2479–86.
Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017;23:242–9.
Google Scholar
Yanir A, Schulz A, Lawitschka A, Nierkens S, Eyrich M. Immune reconstitution after allogeneic haematopoietic cell transplantation: from observational studies to targeted interventions. Front Pediatr. 2021;9:786017.
Google Scholar
Drozdov D, Petermann K, Dougoud S, Oberholzer S, Held L, Güngör T, et al. Dynamics of recent thymic emigrants in pediatric recipients of allogeneic hematopoetic stem cell transplantation. Bone Marrow Transplant. 2022;57:620–6.
Google Scholar
Salzmann-Manrique E, Bremm M, Huenecke S, Stech M, Orth A, Eyrich M, et al. Joint modeling of immune reconstitution post haploidentical stem cell transplantation in pediatric patients with acute leukemia comparing CD34+-selected to CD3/CD19-depleted grafts in a retrospective multicenter study. Front Immunol. 2018;9:1841.
Google Scholar
Bader P. Allo or auto CAR-T cells for refractory BCP-ALL? Blood. 2023;142:122–4.
Google Scholar
Ligon JA, Ramakrishna S, Ceppi F, Calkoen FGJ, Diorio C, Davis KL, et al. INSPIRED Symposium Part 4B: chimeric antigen receptor T cell correlative studies—established findings and future priorities. Transplant Cell Ther. 2024;30:155–70.
Google Scholar
Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci Adv. 2022;8:eabj2820.
Google Scholar
Elavia N, Panch SR, McManus A, Bikkani T, Szymanski J, Highfill SL, et al. Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics. Transfusion. 2019;59:1755–64.
Google Scholar
Biasco L, Izotova N, Rivat C, Ghorashian S, Richardson R, Guvenel A, et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat Cancer. 2021;2:629–42.
Google Scholar
Anderson ND, Birch J, Accogli T, Criado I, Khabirova E, Parks C, et al. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. Nat Med. 2023;29:1700–9.
Google Scholar
Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, et al. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023;7:575–85.
Google Scholar
Ravich JW, Huang S, Zhou Y, Brown P, Pui CH, Inaba H, et al. Impact of high disease burden on survival in pediatric patients with B-ALL treated with tisagenlecleucel. Transplant Cell Ther. 2022;28:73.e1–73.e9.
Google Scholar
Cruz CRY, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122:2965–73.
Google Scholar
Chen Y, Cheng Y, Suo P, Yan C, Wang Y, Chen Y, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2017;179:598–605.
Google Scholar
Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129–39.
Google Scholar
Zhang C, Wang XQ, Zhang RL, Liu F, Wang Y, Yan ZL, et al. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2021;35:1563–70.
Google Scholar
Zhang C, Wang X, Yi H, Wang Y, Yan Z, Zhou J, et al. Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation. J Hematol OncolJ Hematol Oncol. 2024;17:103.
Google Scholar
del Bufalo F, Becilli M, Rosignoli C, De Angelis B, Algeri M, Hanssens L, et al. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL. Blood. 2023;142:146–57.
Google Scholar
Lu W, Lyu H, Xiao X, Bai X, Zhang M, Wang J, et al. Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia. 2024;38:1419–22.
Google Scholar
Ortí G, Peczynski C, Boreland W, O’Reilly M, von Bonin M, Balduzzi A, et al. Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study. Leukemia. 2025;39:431–37.
Dourthe ME, Yakouben K, David A, Thouvenin S, Chaillou D, Caillat-Zucman S, et al. Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia. Br J Haematol. 2024;205:373–7.
Google Scholar
Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, et al. Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front Immunol. 2024;14:1280580.
Breidenbach M, Bader P, Attarbaschi A, Rossig C, Meisel R, Metzler M, et al. Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults. J Hematol OncolJ Hematol Oncol. 2025;18:8.
Google Scholar
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, et al. Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults. Haematologica. 2024;109:3892–903.
Google Scholar
Lecornec N, Dourthe ME, Rabian F, Yakouben K, Chevillon F, Chaillou D, et al. Low disease burden pre-CAR-T cell therapy for children and AYA with B-ALL is associated with an impaired outcome when obtained through intensification of the bridging therapy. Blood. 2023;142:2134.
Lamble A, Bohling SD, Davis KL, Talleur AC, McNerney KO, Naik S, et al. Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: an international consensus statement. HemaSphere. 2025;9:e70247.
Google Scholar
